PreveCeutical Medical Inc.
PREV
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -44.80% | -8.60% | |||
| Depreciation & Amortization | -5.26% | 5.56% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.26% | -7.76% | |||
| Operating Income | 40.26% | 7.76% | |||
| Income Before Tax | 29.89% | 6.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.89% | 6.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.89% | 6.92% | |||
| EBIT | 40.26% | 7.76% | |||
| EBITDA | 40.72% | 7.89% | |||
| EPS Basic | 40.00% | 0.00% | |||
| Normalized Basic EPS | 33.33% | 0.00% | |||
| EPS Diluted | 40.00% | 0.00% | |||
| Normalized Diluted EPS | 33.33% | 0.00% | |||
| Average Basic Shares Outstanding | -0.15% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.15% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||